Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

NCT04882241 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Junction Cancer

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Placebo
DRUG: Cisplatin
DRUG: Capecitabine
DRUG: 5-fluorouracil
DRUG: Docetaxel
DRUG: Oxaliplatin
DRUG: Leucovorin

Sponsor

Merck Sharp & Dohme LLC